Catheter-related InfectionNCT01661361
Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices
An observational study of Catheter-related Infection, run by Universitaire Ziekenhuizen KU Leuven.
Trial summary
Recently, it was reported that when vancomycin levels are determined after port sampling, levels can be falsely increased potentially leading to wrong dose adjustments. The investigators conducted an in vitro experiment using several central venous port devices, in which different flushing techniques were evaluated… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Catheter-related Infection
- What is being tested?
- blood levels
- Type of treatment
- Surgery or procedure
- How many people
- 15 participants
- Where
- No sites listed yet
- Study dates
- Sep 2012to Dec 2012
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients admitted for catheter related infection with methicillin-resistant coagulase-negative staphylococci (MR-CNS) and treated with systemic vancomycin in combination with vancomycin antibiotic lock via central venous port device.
Who may be able to join
- adult patients,
- having central venous port device,
- treated with systemic vancomycin in combination with vancomycin antibiotic lock
Who cannot join
- pregnant women,
- children,
- patients with 'do not resuscitate' (DNR) code
Trial locations and contacts
No sites are listed yet.
About this study
Recently, it was reported that when vancomycin levels are determined after port sampling, levels can be falsely increased potentially leading to wrong dose adjustments.
The investigators conducted an in vitro experiment using several central venous port devices, in which different flushing techniques were evaluated yielding residual vancomycin levels of less than 0.5 mg/L.
In this study, the investigators want to evaluate this flushing technique in vivo in 15 patients admitted with catheter-related infection and treated with systemic vancomycin and vancomycin antibiotic lock.
The purpose is to assess if correct flushing can avoid spurious vancomycin levels obtained via port sampling.
- Conditions
- Catheter-related Infection
- Being tested
- blood levels
- Keywords
- vancomycin, levels, central venous port device, peripherally obtained levels, dose adjustments, TDM
- Medical subject headings
- Catheter-Related Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood levelsProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| vancomycin cohort | Not described Receives: Procedure: blood levels |
What is being measured
The primary outcome is the main question the study is designed to answer.
comparison of central (via port device) and peripherally obtained vancomycin levels: the difference, when using the new flushing technique, is allowed to be maximally 0.5 mg/L
Measured: central and peripheral vancomycin levels will be obtained during steady state: this means starting from the 4th dose (= day 2) of vancomycin treatment. Vancomycin is usually given during 14 days after the last positive blood culture.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2012 (estimated)
- Study startSep 2012
- Primary completionDec 2012 (estimated)
- Study completionDec 2012 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Catheter-related InfectionStudies of the same condition, open and under way.
- More trials run by Universitaire Ziekenhuizen KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Isabelle Spriet, Universitaire Ziekenhuizen KU Leuven
- Investigators
- Isabel Spriet, PharmD PhD, Principal investigator, Pharmacy Dpt, University Hospitals LeuvenJan Verhaegen, MD PhD, Study chair, Medical Diagnostic Sciences, University Hospitals LeuvenHans Prenen, MD PhD, Study chair, Digestive ONcology, University Hosptials LeuvenWilly Peetermans, MD PhD, Study chair, Internal Medicine, University Hospitals LeuvenLudo Willems, PharmD PhD, Study chair, Pharmacy Dpt., University Hosptials Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01661361
- Sponsor's protocol ID
- S54585
- Status last verified
- Aug 2012
- First submitted
- 20 Jul 2012
- Last updated
- 9 Aug 2012
- Results posted
- No
- Data monitoring committee
- No